Olema Pharmaceuticals, Inc.
OLMA
$13.59
-$0.23-1.66%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 8.75M | 6.86M | 5.93M | 3.96M | 4.25M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 57.99M | 50.08M | 45.88M | 37.86M | 34.87M |
| Operating Income | -57.99M | -50.08M | -45.88M | -37.86M | -34.87M |
| Income Before Tax | -53.09M | -46.06M | -42.22M | -43.78M | -30.39M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -53.09M | -46.06M | -42.22M | -43.78M | -30.39M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -53.09M | -46.06M | -42.22M | -43.78M | -30.39M |
| EBIT | -57.99M | -50.08M | -45.88M | -37.86M | -34.87M |
| EBITDA | -57.87M | -49.90M | -45.83M | -37.73M | -34.75M |
| EPS Basic | -0.52 | -0.50 | -0.49 | -0.51 | -0.36 |
| Normalized Basic EPS | -0.32 | -0.32 | -0.31 | -0.25 | -0.22 |
| EPS Diluted | -0.52 | -0.50 | -0.49 | -0.51 | -0.36 |
| Normalized Diluted EPS | -0.32 | -0.32 | -0.31 | -0.25 | -0.22 |
| Average Basic Shares Outstanding | 102.80M | 91.32M | 85.73M | 85.50M | 85.43M |
| Average Diluted Shares Outstanding | 102.80M | 91.32M | 85.73M | 85.50M | 85.43M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |